STUDY SEARCH RESULTS

1 study found for your search request:  3475-641

Study of Pembrolizumab (MK-3475) Plus Enzalutamide Versus Placebo Plus Enzalutamide in Participants ...
Condition: Prostatic Neoplasms
Minimum Age: 18 years, Maximum Age: N/A
Gender: Male
Study ID: NCT03834493
Status: Active, not recruiting
Has Results




Copyright © 2024 · Merck & Co., Inc., Rahway, NJ, USA, and its affiliates. All rights reserved. · This site is intended only for residents of the United States.
Cookie Preferences  Privacy  Terms of Use  U.S. Corporate Site